Christine Cahill

Ms. Christine Cahill

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
Christine CahillChristine Cahill
Christine Cahill
BABassam Alhasson
Bassam Alhasson
NBNeil Blumberg
Neil Blumberg
AMAmber Melvin
Amber Melvin
PKPeter Knight
Peter Knight
MRMajed A. Refaai
Majed A. Refaai

23 September 2020 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
HMHannah L McRae
Hannah L McRae
FKFerhat Kara
Ferhat Kara
CMChelsea Milito
Chelsea Milito
Christine CahillChristine Cahill
Christine Cahill
NBNeil Blumberg
Neil Blumberg
MRMajed A. Refaai
Majed A. Refaai

13 February 2026 in LabMed
Verified
Journal Article
Open access
PDF file
BSBianca Santonastaso
Bianca Santonastaso
HSHannah Spector
Hannah Spector
Christine CahillChristine Cahill
Christine Cahill
KRKhaled Refaai
Khaled Refaai
FAFrank Akwaa
Frank Akwaa
MRMajed A. Refaai
Majed A. Refaai
A 75-year-old male was admitted with worsening anemia and spontaneous bruising in the left abdominal wall and paraspinal region. Laboratory workup revealed low factor XIII (FXIII) activity levels. Cryoprecipitate transfusions raised his FXIII level, but still fluctuated drastically, ranging from 4 to 43% was discharged 3 days later once his bleeding was managed. Three days later, he was readmitted for severe pain and new bruising in his latissimus dorsi and lateral right thigh. CT-scan revealed hemothorax and arterial bleeding requiring an urgent angiogram with embolization. Chromogenic and functional FXIII assays were unable to elucidate an inhibitor at this time. Management included FXIII concentrate, rituximab, and prednisone; the patient was discharged 12 days later with FXIII levels of 50%. After prednisone tapering, FXIII levels decreased drastically. This case exemplified that higher levels of FXIII are required to prevent bleeding diatheses rather than the previously reported minimum of 5% activity. Despite the diagnostic uncertainty of laboratory testing, the shortened half-life of FXIII activity following replacement therapy and favorable response to immunotherapy indicates that the bleeding diathesis was caused by an acquired inhibitor.